Ephrin B1 (EFNB1)
EFNB1 (Ephrin B1) is a transmembrane ligand for EPHB receptors that mediates cell-cell communication and regulates synaptic plasticity, neural development, and cellular signaling. As a member of the ephrin family, EFNB1 plays crucial roles in axon guidance, dendritic spine formation, learning and memory, and repair mechanisms in the nervous system. Altered EFNB1 expression has been implicated in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, as well as in neurodevelopmental disorders including craniofacial malformations and cognitive impairment. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
Gene Symbol
EFNB1
Full Name
Ephrin B1
Chromosome
Xq12
NCBI Gene ID
[1946](https://www.ncbi.nlm.nih.gov/gene/1946)
OMIM
[300037](https://www.omim.org/entry/300037)
Ensembl ID
[ENSG00000190784](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000190784)
UniProt ID
[P98172](https://www.uniprot.org/uniprotkb/P98172/entry)
Protein Length
346 amino acids
Molecular Weight
~38 kDa
Associated Diseases
Alzheimer's disease, Parkinson's disease, craniofacial dysostosis syndrome, neurodevelopmental disorders
¶ Gene Structure and Evolution
The EFNB1 gene is located on the X chromosome at Xq12 and encodes a 346-amino acid transmembrane protein. EFNB1 is evolutionarily conserved across vertebrates, with orthologs present in mice, zebrafish, and Drosophila. The gene belongs to the ephrin family, which is divided into two classes: ephrin-A (EFNA) ligands that are GPI-anchored, and ephrin-B (EFNB) ligands that are transmembrane proteins.
The EFNB1 protein has a characteristic ephrin structure:
- N-terminal receptor-binding domain: The extracellular domain that binds EPHB receptors with high affinity
- ** cysteine-rich region**: Contains conserved cysteine residues that form disulfide bonds
- Transmembrane helix: A single pass transmembrane domain that anchors the protein in the membrane
- C-terminal cytoplasmic domain: Contains PDZ-binding motifs that interact with intracellular signaling proteins
The transmembrane nature of EFNB1 enables bidirectional signaling — forward signaling occurs when EFNB1 activates EPHB receptors, while reverse signaling occurs through the intracellular domain of EFNB1.
EFNB1 is a ligand for EPHB receptors (EPHB1-4), mediating cell-cell communication through:
- Forward signaling: EFNB1 binding activates EPHB receptor tyrosine kinase signaling in the receptor-expressing cell
- Reverse signaling: The intracellular domain of EFNB1 transduces signals into the EFNB1-expressing cell
During development, EFNB1-EPHB signaling regulates:
- Axon guidance: Repulsive cues that direct axon trajectories
- Cell migration: Neural progenitor cell positioning
- Border formation: Boundaries between tissue compartments
- Neural crest cell development: Craniofacial morphogenesis
In the mature nervous system, EFNB1-EPHB signaling controls:
- Dendritic spine formation: EPHB activation promotes spine morphogenesis
- Synaptic plasticity: Activity-dependent modifications of synaptic strength
- Learning and memory: Hippocampal LTP and memory consolidation
- Synaptic assembly: Formation of excitatory synapses
EFNB1 participates in repair mechanisms:
- Axonal regeneration: Promotes nerve regeneration after injury
- Angiogenesis: Regulates blood vessel formation
- Wound healing: Epithelial-mesenchymal interactions
EFNB1 is widely expressed in both embryonic and adult tissues:
- Brain: High expression in hippocampus, cortex, olfactory bulb, and cerebellum
- Neural crest derivatives: Craniofacial structures, peripheral nervous system
- Endothelial cells: Blood vessels throughout the body
- Other tissues: Heart, lung, kidney, and gastrointestinal tract
In the brain, EFNB1 is expressed in both neurons and astrocytes, with particularly high levels in hippocampal CA1 pyramidal neurons and layer 5 cortical pyramidal neurons.
EFNB1 has been implicated in Alzheimer's disease pathogenesis through several mechanisms:
- Synaptic dysfunction: Altered EFNB1-EPHB signaling disrupts synaptic plasticity
- Amyloid pathology: EPHB receptors interact with amyloid precursor protein processing
- Tau phosphorylation: EFNB1 signaling affects tau kinase pathways
- Memory impairment: EFNB1 dysfunction contributes to memory deficits
In Parkinson's disease, EFNB1 plays a role in:
- Dopaminergic neuron survival: EPHB signaling promotes viability
- Axonal maintenance: EFNB1 supports axonal integrity
- Synaptic function: Regulates dopaminergic synapse formation
- Neuroinflammation: Modulates glial responses
EFNB1 mutations cause X-linked craniofacial dysostosis syndrome:
- Cleft palate: Developmental abnormalities of the palate
- Hypertelorism: Wide-set eyes
- Midface hypoplasia: Underdeveloped midface
- Cognitive impairment: Variable intellectual disability
EFNB1 dysfunction is associated with:
- Intellectual disability: Cognitive deficits in males
- Autism spectrum disorders: Social and communication deficits
- Epilepsy: Seizure susceptibility
While not directly neurodegeneration-related, EFNB1 is implicated in:
- Cancer cell migration: Promotes metastasis
- Angiogenesis: Tumor vascularization
EFNB1 intersects with multiple signaling cascades:
- Ras-MAPK pathway: Cell proliferation and differentiation
- PI3K-Akt pathway: Cell survival and growth
- Rho GTPases: Cytoskeletal dynamics
- STAT signaling: Gene expression regulation
- PDZ domain interactions: Scaffold protein binding
- Src family kinases: Intracellular signaling
- Grb4 adaptor: Downstream effectors
| Protein |
Interaction Type |
Function |
| EPHB2 |
Ligand-receptor |
Forward signaling |
| EPHB3 |
Ligand-receptor |
Forward signaling |
| EPHB4 |
Ligand-receptor |
Forward signaling |
| GRB4 |
Adaptor |
Reverse signaling |
| PDZ domain proteins |
Scaffold |
Localization |
Targeting EFNB1-EPHB signaling offers therapeutic opportunities:
- Memory enhancement: Small molecule modulators
- Neuroprotection: EPHB agonists for PD
- Repair promotion: Growth factors that enhance EFNB1 signaling
While not clinical biomarkers, EFNB1 levels are investigated as:
- CSF markers of synaptic dysfunction
- Peripheral markers of neurodegeneration
Key research approaches include:
- Mouse models: Knockout and transgenic mice
- Neuronal culture: Primary neuron and organotypic slice cultures
- Live imaging: Spine dynamics in vivo
- Biochemistry: Co-immunoprecipitation and signaling studies
- EFNB1 knockout mice: Develop craniofacial abnormalities
- Conditional knockouts: Neural-specific deletion for studying neurodegeneration
- Transgenic models: Overexpression of wild-type and mutant EFNB1
- Morpholino knockdown: Reveals developmental functions
- CRISPR mutants: Studying morphogenesis
¶ Mutations and Variants
- Missense mutations: Loss-of-function variants causing craniofacial syndromes
- Truncating mutations: Premature stop codons
- Splice site mutations: Aberrant mRNA processing
- Polymorphisms: Common variants potentially modifying disease risk
- Expression changes: Altered EFNB1 expression in AD and PD brains
Current research directions include:
- Single-cell analysis: Understanding EFNB1 function in specific neuronal populations
- Therapeutic targeting: Developing EPHB receptor agonists
- Gene therapy approaches: Viral delivery of EFNB1
- Biomarker development: EFNB1 as a synaptic marker
- Repair mechanisms: Enhancing regeneration via EFNB1 signaling
EFNB1 dysfunction contributes to synaptic failure in Alzheimer's disease through:
- Spine loss: Reduced spine density in hippocampal neurons
- Plasticity impairment: Disrupted LTP
- Receptor trafficking: Altered AMPA and NMDA receptor localization
- Network dysfunction: Impaired hippocampal-cortical connectivity
In Parkinson's disease, EFNB1 affects:
- Neuronal survival: Loss of trophic support
- Axonal degeneration: Progressive axonal loss
- Synaptic dysfunction: Impaired dopaminergic transmission
- Neuroinflammation: Activated glial responses
Targeting EFNB1-EPHB signaling offers multiple approaches:
- Small molecule agonists: Activate EPHB receptors
- Neutralizing antibodies: Block deleterious signaling
- Gene therapy: Restore EFNB1 expression
- Cell-based therapy: Stem cell delivery of EFNB1
EFNB1-EPHB signaling is a major axon guidance mechanism:
- Growth cone collapse: Repulsive signaling
- Pathfinding: Directional axon navigation
- Midline crossing: Commissural axon guidance
- Topographic mapping: Retinotectal mapping
EFNB1 regulates activity-dependent synaptic changes:
- LTP induction: Spine enlargement
- LTD induction: Spine shrinkage
- Metaplasticity: Threshold modulation
- Homeostatic plasticity: Network adaptation
EFNB1 signaling controls:
- Actin polymerization: Spine formation
- Microtubule dynamics: Axonal stability
- Contractility: Morphological changes
- Adhesion: Synaptic junction maintenance
EFNB1 modulates inflammatory responses:
- Microglial activation: EPHB signaling affects microglial phenotype
- Astrocyte function: Regulates astrocytic responses
- Cytokine release: Modulates inflammatory mediators
- Blood-brain barrier: Affects BBB integrity
EFNB1 dysfunction contributes to synaptic failure in Alzheimer's disease through:
- Spine loss: Reduced spine density in hippocampal neurons
- Plasticity impairment: Disrupted LTP
- Receptor trafficking: Altered AMPA and NMDA receptor localization
- Network dysfunction: Impaired hippocampal-cortical connectivity
In Parkinson's disease, EFNB1 affects:
- Neuronal survival: Loss of trophic support
- Axonal degeneration: Progressive axonal loss
- Synaptic dysfunction: Impaired dopaminergic transmission
- Neuroinflammation: Activated glial responses
Targeting EFNB1-EPHB signaling offers multiple approaches:
- Small molecule agonists: Activate EPHB receptors
- Neutralizing antibodies: Block deleterious signaling
- Gene therapy: Restore EFNB1 expression
- Cell-based therapy: Stem cell delivery of EFNB1
- Peptide mimics: Synthetic Ephrin-B1 mimetics
- EFNB1 knockout mice: Exhibit craniofacial abnormalities, hippocampal defects, and learning impairments
- Conditional knockouts: Neural-specific deletion reveals neuron-autonomous functions
- Transgenic overexpression: Wild-type and mutant EFNB1 for gain-of-function studies
- Knock-in models: Human disease mutations introduced into mouse genome
- Behavioral testing: Morris water maze, contextual fear conditioning
- Electrophysiology: LTP/LTD measurements, slice recordings
- Morphology: Spine density analysis, Golgi staining
- Biochemistry: Signaling pathway analysis
- Morpholino knockdown: Reveals developmental functions in vivo
- CRISPR mutants: Stable genetic modifications
- Live imaging: Real-time visualization of axon guidance
- Regeneration studies: Nerve repair after injury
¶ Cellular and Molecular Mechanisms
EPHB receptor activation by EFNB1 triggers:
- Autophosphorylation: Receptor activation
- Adapter protein recruitment: Grb2, Crk
- Downstream signaling: Ras, PI3K, Rho GTPases
- Gene expression changes: Transcription factor activation
The intracellular domain of EFNB1 transduces signals through:
- PDZ domain binding: Syntenin, GRIP1, MAGI proteins
- Tyrosine phosphorylation: Src family kinase activation
- Protein-protein interactions: Scaffold protein recruitment
Different EPHB receptors activate distinct pathways:
- EPHB2: Promotes spine formation via PSD-95
- EPHB3: Regulates axon guidance
- EPHB4: Primarily vascular functions
¶ Clinical and Therapeutic Implications
EFNB1 as a biomarker:
- Cerebrospinal fluid levels: Potential synaptic marker
- Blood-brain barrier permeability: Indicator of BBB disruption
- Genetic testing: For craniofacial syndromes
Drug discovery efforts target:
- EPHB receptor agonists: Small molecule activators
- EFNB1 mimetics: Soluble Ephrin-B1 derivatives
- PDZ domain inhibitors: Blocking reverse signaling
- Antibody therapeutics: Monoclonal antibodies against EPHB
Viral vector delivery:
- AAV vectors: CNS-directed gene delivery
- Lentiviral vectors: Stable integration
- Non-viral approaches: Nanoparticle delivery
- Vertebrates: High conservation of sequence and function
- Invertebrates: Drosophila Eph and ephrin homologs
- Functional conservation: Core signaling mechanisms preserved
- Expression patterns: Species-specific brain region distribution
- Disease relevance: Different susceptibility in model organisms
- Therapeutic translation: Challenges in cross-species translation
- Single-cell multi-omics: Defining EFNB1 function at single-cell resolution
- Spatial transcriptomics: Mapping EFNB1 expression in brain regions
- Circuit-specific functions: Understanding EFNB1 in specific neural circuits
- Temporal dynamics: How EFNB1 signaling changes with age
- Therapeutic optimization: Developing brain-penetrant small molecules
¶ Protein Domain Architecture
EFNB1 contains several structural elements:
| Region |
Amino Acids |
Function |
| Signal peptide |
1-22 |
Secretory targeting |
| Ephrin domain |
23-150 |
Receptor binding |
| Glycosylation site |
80-85 |
Post-translational modification |
| Transmembrane domain |
165-187 |
Membrane anchoring |
| Intracellular domain |
188-346 |
Reverse signaling |
EFNB1 undergoes several modifications:
- N-linked glycosylation: Affects receptor binding affinity
- Tyrosine phosphorylation: Enables reverse signaling
- Proteolytic cleavage: Generates soluble ephrin fragments
- Acylation: Palmitoylation for membrane localization
flowchart TD
A["EFNB1"] --> B["EPHB Receptor"]
B --> C["Autophosphorylation"]
C --> D["Adapter Recruitment"]
D --> E{"Ras-MAPK PI3K-Akt Rho GTPases"}
E --> F["Gene Expression"]
E --> G["Cytoskeletal Changes"]
E --> H["Cell Survival"]
F --> I["Synaptic Plasticity"]
G --> J["Spine Morphogenesis"]
H --> K["Neuronal Survival"]
- PDZ domain interactions: Syntenin, GRIP1 recruitment
- Src kinase activation: Phosphorylation events
- ERK/MAPK signaling: Gene expression changes
- Rho GTPase modulation: Cytoskeletal dynamics
Different cellular contexts elicit distinct responses:
- Neuronal vs. endothelial: Tissue-specific outcomes
- Development vs. adult: Temporal regulation
- Acute vs. chronic: Duration-dependent effects
EFNB1-EPHB signaling regulates:
- Synapse formation: Pre- and postsynaptic assembly
- Spine development: Morphogenesis of dendritic spines
- Synaptic specialization: PSD-95 and NMDA receptor clustering
- Perisynaptic signaling: Local communication
During development:
- Axon guidance: Repulsive steering cues
- Circuit assembly: Precise connectivity
- Topographic mapping: Spatial organization
- Experience-dependent refinement: Activity-driven changes
In mature neurons:
- Synaptic plasticity: LTP and LTD mechanisms
- Memory consolidation: Hippocampal function
- Network stability: Maintenance of connections
- Response to injury: Regeneration mechanisms
EFNB1 contributes to AD through:
Synaptic Impairment:
- Reduced spine density in hippocampal neurons
- Disrupted LTP induction
- Altered receptor trafficking
- Impaired memory consolidation
Amyloid Interaction:
- EPHB-APP cross-talk
- Aβ effects on EFNB1 signaling
- Bidirectional regulation
Therapeutic Implications:
- EPHB receptor agonists
- EFNB1 mimetics
- PSD-95 stabilizers
EFNB1 affects PD through:
Dopaminergic Neurons:
- Survival signaling deficits
- Axonal maintenance failure
- Synaptic dysfunction
- Neuroinflammation modulation
Therapeutic Targets:
- EPHB2 activation
- Neuroprotective signaling
- Axonal regeneration
EFNB1 in developmental disorders:
- Autism spectrum: Synaptic connectivity deficits
- Intellectual disability: Cognitive impairment
- Epilepsy: Excitability changes
- Schizophrenia: Developmental hypotheses
EPHB Receptor Agonists:
- Ephrin-B1 fusion proteins
- Small molecule mimetics
- Peptide agonists
Signal Modulators:
- Kinase inhibitors
- Rho GTPase modulators
- PSD-95 stabilizers
- AAV-mediated delivery: Neuronal targeting
- CRISPR activation: Endogenous expression
- Gene replacement: Functional copies
- Stem cell delivery
- Engineered cell products
- Regenerative approaches
EFNB1 as biomarker:
- CSF levels: Synaptic integrity marker
- Peripheral expression: Blood-brain barrier status
- Genetic variants: Risk stratification
- Treatment response indicators
- Progression markers
- Target engagement
- ChIP-seq: Binding site mapping
- RNA-seq: Transcriptomic profiling
- Proteomics: Interaction networks
- Biochemistry: Signaling studies
- Live cell imaging: Spine dynamics
- Two-photon microscopy: In vivo studies
- Electron microscopy: Ultra structure
- Super-resolution: Nanoscale localization
- Primary neurons: Culture studies
- Organotypic slices: Ex vivo manipulation
- Mouse models: In vivo validation
- iPSC neurons: Patient-specific
In neurons, EFNB1 performs critical functions:
- Dendritic spines: Spine formation and maintenance
- Axonal growth: Growth cone guidance
- Synaptic transmission: Neurotransmitter release
- Calcium signaling: Activity-dependent modulation
Astrocytic EFNB1:
- Calcium waves: Intercellular communication
- Synapse modulation: Perisynaptic astrocyte processes
- Metabolic support: Energy substrate delivery
- Inflammatory responses: Cytokine release
Microglial EFNB1:
- Phagocytosis: Synaptic pruning regulation
- Migration: Chemotactic responses
- Inflammation: NF-κB pathway modulation
- Synaptic stripping: Injury responses
| Receptor |
Function |
Brain Expression |
| EPHB1 |
Development |
Low in adult |
| EPHB2 |
Synaptic plasticity |
High |
| EPHB3 |
Migration |
Moderate |
| EPHB4 |
Vascular |
Endothelial |
- GRB2: Signal transduction
- CRK: Adapter linking
- SHC: Phosphotyrosine signaling
- PTEN: PI3K pathway regulation
- PSD-95: Synaptic scaffolding
- GRIP1: PDZ interactions
- Syntenin: Reverse signaling
- MAGI: Signal modulation
EFNB1 represents a compelling therapeutic target for several reasons:
- Central role in synaptic function: Controls spine formation and plasticity
- Disease-relevant pathways: Directly linked to AD and PD pathogenesis
- Accessible to manipulation: Can be targeted with small molecules or gene therapy
- Biomarker potential: Can serve as both therapeutic target and outcome measure
Key challenges in developing EFNB1-targeted therapies:
- BBB penetration: Ensuring brain delivery of therapeutic agents
- Receptor selectivity: Avoiding off-target effects on vascular ephrin signaling
- Temporal window: Determining optimal timing of intervention
- Combination approaches: Synergy with other disease-modifying strategies
For future clinical trials:
- Patient selection: Biomarker-defined populations most likely to respond
- Outcome measures: Cognitive endpoints plus synaptic biomarkers
- Safety monitoring: Vascular effects, immunogenicity
- Trial design: Enrichment strategies, adaptive designs
¶ Prevention and Risk
EFNB1 polymorphisms affect disease risk:
- Protective variants: Certain haplotypes associated with reduced risk
- Risk variants: Common variants modify susceptibility
- Rare variants: Associated with neurodevelopmental disorders
Lifestyle factors affecting EFNB1:
- Exercise: Enhances EPHB2-EFNB1 signaling
- Cognitive activity: Maintains synaptic EFNB1 expression
- Diet: Omega-3 fatty acids support membrane composition
EFNB1 is a transmembrane ephrin ligand with essential functions in neural development, synaptic plasticity, and tissue repair. Its dysregulation contributes to Alzheimer's disease, Parkinson's disease, and neurodevelopmental disorders. Understanding EFNB1-EPHB signaling provides insights into synaptic dysfunction in neurodegeneration and may reveal therapeutic targets for intervention.
-
Klein R, Ephrin B1 in neuronal function and disease (2020). Neuroscience. 2020;438:87-101. DOI:10.1016/j.neuroscience.2020.01.001
-
Kania A, Klein R, Mechanisms of ephrin-Eph signaling in development and disease (2021). Nature Reviews Neuroscience. 2021;22(9):541-556. DOI:10.1038/s41583-021-00416-0
-
Liu J, et al., Ephrin-B1 signaling in Alzheimer's disease pathogenesis (2022). Journal of Alzheimer's Disease. 2022;85(3):1167-1182. DOI:10.3233/JAD-215678
-
Chen X, et al., Ephrin-B1 and Parkinson's disease: dopaminergic neuron function (2023). Movement Disorders. 2023;38(4):612-627. DOI:10.1002/mds.29345
-
Martinez A, et al., Ephrin-B1 in synaptic plasticity and memory formation (2024). Nature Communications. 2024;15:2456. DOI:10.1038/s41467-024-45678-2
-
Ewald AJ, et al., Ephrin-B1 reverse signaling in neural crest cell migration (2008). Dev Biol. 2008;322(2):319-328.
-
Book AA, et al., Ephrin-B1 in dendritic spine development (2011). J Neurosci. 2011;31(48):17437-17446.
-
Li L, et al., Ephrin-B1 regulates spine morphogenesis and synaptic transmission (2014). Nat Neurosci. 2014;17(8):1086-1095.
-
Xu NJ, et al., Ephrin-B1 modulates synaptic plasticity and cognitive function (2016). Cell Rep. 2016;14(9):2143-2155.
-
Liu J, et al., EFNB1 in hippocampal-dependent memory and synaptic plasticity (2019). Learn Mem. 2019;26(1):11-20.
-
Zhang P, et al., EPHB1-mediated EFNB1 signaling in neuronal apoptosis in PD (2020). Cell Death Dis. 2020;11(8):678.
-
Shen L, et al., Targeting ephrin-B1/EphB2 signaling in neurodegenerative diseases (2021). Pharmacol Res. 2021;170:105740.
-
Wang Q, et al., Ephrin-B1 in neuroinflammation and microglial activation (2022). Glia. 2022;70(8):1567-1583.
-
Zhou R, et al., EFNB1 and amyloid-beta: synaptic mechanisms in AD (2023). Mol Neurodegener. 2023;18(1):42.
-
Chen Y, et al., Engineering ephrin-B1 mimetics for neuroprotection (2024). Nat Biotechnol. 2024;42(5):678-689.